Wen-Kai Weng, MD, PhD

Publications

• Cancer vaccines and T cell therapy. Rezvani K, Brody JD, Kohrt HE, Logan AC, Advani R, Czerwinski DK, Weng WK, Negrin RS, Carlton V, Faham M, Levy R, Barrett J. Biol Blood Marrow Transplant. 2013; 19 (1 Suppl): S97-S101
• Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, Shizuru JA, Johnston LJ, Laport GG, Weng WK, Benjamin JE, Schaenman J, Brown J, Ramirez J, Zehnder JL, Negrin RS, Miklos DB. Blood. 2012; 119 (25): 6145-54
• Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW, Stockdale FE, Mollick JA, Chen L, Levy R. J Clin Invest. 2012; 122 (3): 1066-75
• Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. Chen AI, Negrin RS, McMillan A, Shizuru JA, Johnston LJ, Lowsky R, Miklos DB, Arai S, Weng WK, Laport GG, Stockerl-Goldstein K. Bone Marrow Transplant. 2012; 47 (4): 516-21
• The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. Kelly-Sell MJ, Kim YH, Straus S, Benoit B, Harrison C, Sutherland K, Armstrong R, Weng WK, Showe LC, Wysocka M, Rook AH. Am J Hematol. 2012; 87 (4): 354-60
• Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, Johnston LJ, Shizuru JA, Miklos D, Arai S, Benjamin JE, Weng WK, Negrin RS. Biol Blood Marrow Transplant. 2011; 17 (11): 1679-87
• Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. Weng WK, Negrin RS, Lavori P, Horning SJ. J Clin Oncol. 2010; 28 (2): 279-84
• Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma. Arai S, Letsinger R, Wong RM, Johnston LJ, Laport GG, Lowsky R, Miklos DB, Shizuru JA, Weng WK, Lavori PW, Blume KG, Negrin RS, Horning SJ. Biol Blood Marrow Transplant. 2010; 16 (8): 1145-54
• Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. Weng WK, Levy R. Leuk Lymphoma. 2009; 50 (5): 723-7
• Immunoglobulin G Fc Receptor Polymorphisms Do Not Correlate with Response to Chemotherapy or Clinical Course in Patients with Follicular Lymphoma Weng WK, Levy R. Leuk Lymphoma. 2009; 50 (9): 1494-1500
• TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, Johnston LJ, Arai S, Weng WK, Hoppe RT, Lavori PW, Blume KG, Negrin RS, Strober S, Lowsky R. Blood. 2009; 114 (5): 1099-109
• Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Timmerman JM, Vose JM, Czerwinski DK, Weng WK, Ingolia D, Mayo M, Denney DW, Levy R. Leuk Lymphoma. 2009; 50 (1): 37-46
• A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, Huang J, Dahle C, Halwani A, Levy R, Weiner GJ. Clin Cancer Res. 2008; 14 (20): 6697-703
• The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Luqman M, Klabunde S, Lin K, Georgakis GV, Cherukuri A, Holash J, Goldbeck C, Xu X, Kadel EE, Lee SH, Aukerman SL, Jallal B, Aziz N, Weng WK, Wierda W, O'Brien S, Younes A. Blood. 2008; 112 (3): 711-20
• Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless their response to induction chemotherapy. Weng WK, Czerwinski D, Levy R. Blood. 2007: 109 951-3
• Immune-mediated antitumor effects with antibody therapy. Weng WK, American Society of Clinical Oncology Educational Book. 2005: 200-4
• Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. J Clin Oncol. 2004: 22 4717
• Hepatitis C virus (HCV) and lymphomagenesis. Weng WK, Levy S. Leuk Lymphoma. 2003; 44 (7): 1113-20
• Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. Weng WK, Levy R. J Clin Oncol. 2003; 21 (21): 3940-7
• Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Weng WK, Levy R. Blood. 2001; 98 (5): 1352-7
• Differential induction of DNA-binding activities following CD19 cross-linking in human B lineage cells. Weng WK, Shah N, O'Brien D, Van Ness B, LeBien TW. J Immunol. 1997; 159 (11): 5502-8
• Signaling through CD19 activates Vav/mitogen-activated protein kinase pathway and induces formation of a CD19/Vav/phosphatidylinositol 3-kinase complex in human B cell precursors. Weng WK, Jarvis L, LeBien TW. J Biol Chem. 1994; 269 (51): 32514-21
• Functional effect of IL-7-enhanced CD19 expression on human B cell precursors. Wolf ML, Weng WK, Stieglbauer KT, Shah N, LeBien TW. J Immunol. 1993; 151 (1): 138-48